Abstract
Eight expert orthopedic pathologists voluntarily reviewed the clinicoradiologic and histologic data from 12 selected cases coded as osteosarcoma over the past seven years (procured from a total of 40 cases) from the files of the University of North Carolina and Wake Forest University. The study sample was chosen to include a full spectrum of histologic grades and subtypes including conventional, low-grade central, chondroblastoma-like, osteoblastoma-like, small cell, telangiectatic, parosteal, and periosteal variants. Participants were asked to render a diagnosis, provide a histologic grade (if applicable), and offer an opinion as to whether the patient could benefit from chemotherapy. Uniform agreement regarding the diagnosis of osteosarcoma was observed in 7 cases (58 hr %), including the most common, conventional subtypes, and the telangiectatic, parosteal, and periosteal variants. Among the remaining 5 cases, the consensus majority (> 4) also was osteosarcoma. However, additional diagnoses ranged from osteoblastoma to high-grade osteosarcoma in two tumors, mesenchymal chondrosarcoma versus small cell osteosarcoma in one, fibrosarcoma and malignant fibrous histiocytoma versus fibroblastic osteosarcoma in another, and clear cell chondrosarcoma versus chondroblastoma versus chondroblastic osteosarcoma in a fifth. Among osteosarcoma diagnoses, histologic grading ranged from low- to high-grade osteosarcoma in 6 tumors (50%). Regarding the necessity for chemotherapy, there was disagreement from at least one consultant in 7 cases (58 hr %). Evaluation of the intraclass correlation coefficient revealed modest agreement with respect to histologic grade and therapy but poor agreement for diagnosis, the latter reflecting the wide range of diagnoses in a minority of cases. Interobserver variability exists among expert orthopedic pathologists for determining the diagnosis, histologic grade, and necessity of chemotherapy in less common forms of osteosarcoma. A more objective histologic grading and scoring system for osteosarcoma should be established, followed by multi-institutional studies assessing the usefulness of the system as it relates to the necessity of chemotherapy and survival.
